This company is no longer in business. Investors can get details about any potential exits or failures here.

NowRx

NowRx

Testing the Waters
Growth Stage

Technology-driven, on-demand pharmacy providing free, same-day delivery

Technology-driven, on-demand pharmacy providing free, same-day delivery

Overview

Raised to Date: Raised: $3,635,310

Total Commitments ($USD)

Platform

SeedInvest

Start Date

08/26/2021

Close Date

Testing the Waters

Min. Goal
Funded
Max. Goal
Funded
Min. Investment

$998

Security Type

Equity - Preferred

SEC Filing Type

Test the Waters / RegA+    Open SEC Filing

Price Per Share

$10.85

Pre-Money Valuation

$275,000,000

Rolling Commitments ($USD)

Status
Funded
Reporting Date

10/30/2021

% of Min. Goal
Funded
% of Max. Goal
Funded
Likelihood of Max
Funded
Avg. Daily Raise

$93,213

# of Reservations

906

Momentum
Funded
Create a free account today to gain access to KingsCrowd analytics.
Year Founded

2015

Industry

Healthcare & Pharmaceuticals

Tech Sector

HealthTech

Location

Mountain View, California

NowRx, with a valuation of $275 million, is testing the waters on SeedInvest. The digital health platform provides both same-day delivery of medicines and telehealth services through its software and robotics. The pharmacy management and logistics system of NowRx, QuickFill, offers online prescribing, free same-day prescription delivery, insurance approval, payment assistance, and live customer service. NowRx generated $13.4 million in revenue in 2020 and reached $9.79 in revenue in the first half of 2021. Cary Breese and Sumeet Shoekand founded NowRx in 2015. The current crowdfunding campaign has a minimum target of $2,550,000 and a maximum target of $75,000,000. The campaign proceeds will be used for research and development, growth into new geographical regions, and expansion of operations to meet increasing consumer demand.
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
NowRx 05/19/2022 SeedInvest $275,000,000 $30,006,323 Equity - Preferred Funded RegA+
NowRx 10/04/2021 SeedInvest $275,000,000 $3,635,310 Equity - Preferred Funded Test the Waters / RegA+
NowRx 06/18/2020 SeedInvest $65,000,000 $20,002,878 Equity - Preferred Funded RegA+
NowRx 06/29/2018 SeedInvest $20,000,000 - Equity - Preferred Funded RegA+
NowRx 07/18/2017 SeedInvest $6,000,000 - Convertible Note Funded RegCF / RegD 506(c)
Create a free account today to gain access to KingsCrowd analytics.

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Valuation History

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Employee History

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
NowRx on SeedInvest 2021
Platform: SeedInvest
Security Type: Equity - Preferred
Valuation: $275,000,000
Price per Share: $10.85

Follow company

Follow NowRx on SeedInvest 2021

Buy NowRx's Deal Report

Warning: according to the close date for this deal, NowRx may no longer be accepting investments.

NowRx Deal Report

Get KingsCrowd’s comprehensive report on NowRx including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether NowRx is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the NowRx deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge